Gilead Sciences (GILD) Tops Q3 EPS by 38c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. MSFT
6. NVDA
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Gilead Sciences (GILD) Tops Q3 EPS by 38c

Gilead Sciences Announces Third Quarter 2022 Financial Results

October 27, 2022 4:01 PM EDT

Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion

Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion

Oncology Sales Increased 79% Year-Over-Year to $578 million

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2022.

Chairman and Chief Executive Officer of Gilead Sciences, Daniel ODay said: This was another very strong quarter across the business. In HIV, treatment and prevention markets continue to grow with further share gains for Biktarvy... More